pSivida Corp. (NASDAQ:PSDV; ASX:PVA), a specialty pharmaceutical company that is a leader in the development of sustained release ophthalmic drug treatments, today announced that the Company’s Vice President of Research, Dr. Hong Guo, will present a paper at the 5 th Ocular Diseases and Drug Development Conference in San Francisco on March 21. Dr. Guo’s presentation will take place at 10:30 a.m.
Dr. Guo’s presentation entitled “Sustained delivery of proteins and anti-bodies” is expected to discuss recent developments in pSivida’s Tethadur technology.
“One of the many challenges to the pharmaceutical industry is to develop effective delivery systems for protein and antibody drugs,” said Dr. Paul Ashton, President and CEO of pSivida. “Dr. Guo will describe results we have had with our proprietary Tethadur system, which is based on bioerodible, nanostructured, porous silicon. With the large number of biologic patents expiring and the development of the Bio-similar field, improved protein delivery will become increasingly important.”
pSivida has previously announced a technology evaluation agreement with a leading global biopharmaceutical company investigating the use of this technology in ophthalmology.The Ocular Diseases and Drug Development Conference promotes the discovery of ocular disease development by bringing together leading scientists, researchers and experts to discuss and collaborate on the latest research and development, safety assessment, regulatory issues and drugs in development for combating and curing age-related macular degeneration (AMD), diabetic retinopathy, glaucoma, DME, uveitis and other ocular diseases. Among those participating are representatives from most of the pharmaceutical companies that are involved in the development of treatments for these conditions. About pSivida Corp. pSivida Corp., headquartered in Watertown, MA, develops tiny, sustained release, drugs delivery products designed to release drugs at a controlled and steady rate for months or years. pSivida is currently focused on treatment of chronic diseases of the back of the eye utilizing its core technology systems, Durasert™ and BioSilicon™. Two FDA-approved products, Vitrasert™ and Retisert™ are licensed to Bausch & Lomb. The company has licensed ILUVIEN® for DME to Alimera Sciences and that product has received marketing authorization in Austria, France, Germany, Portugal, Spain and the UK. pSivida has clinical trials ongoing for the treatment of posterior uveitis and glaucoma and ocular hypertension. Other technologies under development by pSivida include protein and antibody delivery systems in early clinical stages.